Last reviewed · How we verify

NCT05909410

Perception About Benefits and Risks Related to Combined Hormonal Contraceptives Use in Patients With Lynch Syndrome

Status unknown Last updated 18 June 2023
What this trial tests

trial testing Survey investigating the CHC use and patients' perception about the relationship between CHC and cancer, diseases and symptoms in Lynch Syndrome in 180 participants. Status unknown.

Timeline
1 July 2023
Primary endpoint
1 July 2023
1 September 2023

Quick facts

Lead sponsorPiazza della Vittoria 14 Studio Medico - Ginecologia e Ostetricia
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment180
Start date1 July 2023
Primary completion1 July 2023
Estimated completion1 September 2023
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Piazza della Vittoria 14 Studio Medico - Ginecologia e Ostetricia

Who can join

Adults 18 to 52, female only, with Lynch Syndrome or Contraception. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Combined hormonal contraceptives (CHCs), according to the opinion by The Manchester International Consensus Group, should be considered for women wishing contraception because also positively impact endometrial cancer and ovarian cancer risk. The awareness of the effects of hormonal therapies in women at high risk of developing endometrial cancer, colorectal, breast, or ovarian cancer, such as those affected by Lynch syndrome (LS), is currently limited, with few published studies addressing these populations. Making informed decisions about CHC use in this context necessitates careful consideration of individual cancer risk and the potential benefits and risks associated with CHC use. Accurate information regarding the oncological risks associated with CHC use is essential for facilitating shared decision-making between women and their healthcare providers in this patient population. This prospective study aims to evaluate the knowledge, attitudes, and beliefs of women with LS concerning CHCs and their potential effects on specific disease development and cancer risk, comparing them to the general population. By considering psychosocial factors and individual perceptions of cancer risk, this study seeks to contribute to informed decision-making, personalized counseling, and improved strategies for gynecologic cancer risk management in women with LS.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Perception about benefits and risks related to combined hormonal contraceptives use in women with Lynch syndrome.
    Barra F, Perrone U, Ferrero S, Bogliolo S, et al · · 2024 · PMID 38920120 · DOI 10.1080/07853890.2024.2370568

Verify or expand the search:

Other recruiting trials for Lynch Syndrome

Currently open trials in the same condition.

Other Piazza della Vittoria 14 Studio Medico - Ginecologia e Ostetricia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05909410.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing